Upfront Briefing
The tape said “risk-on,” but biotech said “show me the post-money.” Trevi priced a $150M underwritten common-stock offering, Spyre closed its deal with full overallotment for $463.5M gross, and Kailera priced a $625M IPO at the top of range.
That is the key Friday read-through: public-market appetite is open, but it is rewarding scaled stories and still making the rest of biotech wear the dilution math in real time. Elsewhere, J&J’s return of bota-vec to MeiraGTx for $25M was the notable gene-therapy unwind of the day.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,041.3 |
+0.3% |
+2.9% |
| Nasdaq 100 |
26,333.0 |
+0.5% |
+4.3% |
| Russell 2000 |
2,719.6 |
+0.2% |
+9.6% |
| Healthcare (XLV) |
146.6 |
(0.8%) |
(5.3%) |
| Biotech (XBI) |
135.5 |
(0.7%) |
+11.1% |
| Nasdaq Biotech (NBI) |
6,035.1 |
(0.7%) |
+5.7% |
| Clinical Trials (BBC) |
46.4 |
(0.5%) |
+18.5% |
|
- The YTD split is still the key read: XBI is up 11.1% versus XLV down 5.3%, a sharp divergence between biotech beta and defensive healthcare even after Thursday’s pullback.
- Broad indices stayed risk-on on easing Middle East tensions and supportive earnings — S&P 500 and Nasdaq 100 hit fresh records — but biotech lagged the green tape, with XBI and NBI both down 0.7% and XLV off 0.8% as investors absorbed fresh share-count expansion.
- Market data: U.S. close Thu 16-Apr-2026.
The Big 3
|
1
|
Trevi Therapeutics prices $150M underwritten stock offering
|
- Trevi Therapeutics announced pricing of a $150 million underwritten offering of common stock after previously launching the deal.
- Why it matters: The immediate takeaway is simple: Trevi bought itself funding visibility, but only by forcing investors to absorb a meaningful share-count reset. Pricing 37.5M shares at $4.00 gives the market a clean read on the dilution required to bridge to the company’s next value inflection points.
- Source: PR
- More: PR
|
|
2
|
Spyre Therapeutics closes public offering; full overallotment
|
- Spyre Therapeutics announced the closing of its public offering and the full exercise of underwriters’ option for gross proceeds of $463.5 million.
- Why it matters: Dilution is real, but the signal that matters more is access: Spyre cleared a very large follow-on plus the full overallotment, underscoring that high-conviction names can still tap deep pools of capital. For investors, that sharply reduces balance-sheet risk, but it also raises the bar for near-term execution and multiple expansion against a larger share base.
-
Source:
PR
|
|
3
|
Kailera prices $625M IPO at $16 per share
|
- Kailera priced its initial public offering at $16 per share, raising $625 million gross and landing at the top of its marketed range.
- Why it matters: Kailera stands apart because this is an IPO clearing at scale in obesity, not just another follow-on. A $625M deal at the top of range is a strong read on crossover appetite and on exit paths for late-stage private companies with category-sized stories. Pair that with Alamar's upsized pricing earlier this week and the 2026 issuance window looks stronger, not thinner.
- Source: PR
- More: Reuters
|
Everything Else that broke
- J&J returned botaretigene sparoparvovec, its gene therapy for inherited retinal disease, to MeiraGTx for $25M upfront — a notable unwind in the gene-therapy tape. — Fierce Biotech
- Aligos sold China rights to its HBV asset to Amoytop in a deal worth up to $445M. — Fierce Biotech
- RFK Jr. defended FDA commissioner Marty Makary at a House hearing, keeping the policy tape firmly in view. — Endpoints
- Trump nominated Erica Schwartz as next CDC director. — BioPharma Dive
- OpenAI launched GPT-Rosalind, a biopharma-focused model pitched at research and drug-development workflows. — Endpoints
- Merck PD-1/VEGF data highlighted in AACR ’26 preview. — BioSpace
- Bioxodes outlined pivotal trial design for BIOX-101 in intracerebral hemorrhage. — PR
- AB Science updated its clinical-development program, including next steps across masitinib-led pipeline programs. — PR
- Autoimmune T cell engagers diverge from oncology roots. — BioCentury
- Carbios reported fiscal-year 2025 financial results. — PR
- PacBio set its Q1 2026 financial-results date for May 7. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Signant Health to acquire Ametris in definitive agreement. — PR
VC / Private Financings
- Neomorph closes $100M Series B led by Deerfield Management, joined by Regeneron Ventures, Longwood Fund, Alexandria Venture Investments and Binney Street Capital. — PR
- Scala Biodesign raises $16M Series A led by Grove Ventures, joined by TLV Partners, Deep Insight, IT-Farm and Bullet Ventures. — PR
IPOs / Follow-Ons
- Trevi Therapeutics prices $150M underwritten stock offering. — PR
- Spyre Therapeutics closes public offering with full overallotment for $463.5M gross. — PR
- Kailera prices $625M IPO at $16 per share. — PR
- Alamar Biosciences priced an upsized IPO at $17 per share. — Reuters
- JATT II Acquisition Corp prices $60M IPO. — PR
Things that make you go hmmm ...
Top selling orphan drugs in 2032. Source: Evaluate Pharma.
Academic Corner - Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial. — Nature Medicine
- FDA new drug approvals in Q1 2026. — Nature RDD
- Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease. — NEJM
|
